4.10Open4.10Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover294.74%IV6.81%PremiumAug 16, 2024Expiry Date3.52Intrinsic Value100Multiplier23DDays to Expiry0.58Extrinsic Value100Contract SizeAmericanOptions Type0.8617Delta0.0343Gamma2.03Leverage Ratio-0.0303Theta0.0021Rho1.75Eff Leverage0.0048Vega
Outlook Therapeutics Stock Discussion
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics has received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation for treating wet AMD. This makes it the first ophthalmic bevacizumab formulation approved for wet AMD in the EU. This authorization covers all 27 EU Member States and will extend to Icela...
In an era where medical advancements are pivotal to enhancing quality of life, a significant breakthrough has been made in the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss among the elderly. Outlook Therapeutics, Inc. has received a positive opinion from the European Union's Committee for Me...
No comment yet